HER2 Positive Metastatic Breast Cancers Clinical Trial Using ONT-380, Capecitabine and Trastuzumab

- The folks at Oncothyreon Inc. are studying the effects of ONT-380; Capecitabine; Trastuzumab on HER2 Positive Metastatic Breast Cancers in individuals ages 18 years and older. This clinical trial is slated to start December 2013 and is expected to end circa June 2016.

Overall Study Contact Info
StatusName Contact Phone
Recruiting

This study is officially titled, "A Phase 1b, Open-label Study to Assess the Safety and Tolerability of ONT-380 Combined With Capecitabine and Trastuzumab, Alone and in Combination in HER2+ Metastatic Breast Cancer."

Locations

University of Colorado

Aurora, Colorado - Recruiting

Sarah Cannon Research Institute

Nashville, Tennessee - Recruiting

Providence Cancer Center

Portland, Oregon - Not yet recruiting

Mary Crowley Cancer Research Centers

Dallas, Texas - Not yet recruiting

MD Anderson Cancer Center

Houston, Texas - Not yet recruiting

Northwest Medical Specialties

Tacoma, Washington - Not yet recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.